- Home
- ORIC vs MLYS Comparison
ORIC vs MLYS Comparison
Compare ORIC & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORIC
- MLYS
- Stock Information
- Founded
- ORIC 2014
- MLYS 2019
- Country
- ORIC United States
- MLYS United States
- Employees
- ORIC N/A
- MLYS N/A
- Industry
- ORIC Biotechnology: Pharmaceutical Preparations
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- ORIC Health Care
- MLYS Health Care
- Exchange
- ORIC Nasdaq
- MLYS Nasdaq
- Market Cap
- ORIC 633.7M
- MLYS 634.6M
- IPO Year
- ORIC 2020
- MLYS 2023
- Fundamental
- Price
- ORIC $10.39
- MLYS $10.44
- Analyst Decision
- ORIC Strong Buy
- MLYS Strong Buy
- Analyst Count
- ORIC 9
- MLYS 2
- Target Price
- ORIC $18.75
- MLYS $30.00
- AVG Volume (30 Days)
- ORIC 572.3K
- MLYS 273.6K
- Earning Date
- ORIC 03-10-2025
- MLYS 11-11-2024
- Dividend Yield
- ORIC N/A
- MLYS N/A
- EPS Growth
- ORIC N/A
- MLYS N/A
- EPS
- ORIC N/A
- MLYS N/A
- Revenue
- ORIC N/A
- MLYS N/A
- Revenue This Year
- ORIC N/A
- MLYS N/A
- Revenue Next Year
- ORIC N/A
- MLYS N/A
- P/E Ratio
- ORIC N/A
- MLYS N/A
- Revenue Growth
- ORIC N/A
- MLYS N/A
- 52 Week Low
- ORIC $6.33
- MLYS $8.58
- 52 Week High
- ORIC $16.65
- MLYS $16.91
- Technical
- Relative Strength Index (RSI)
- ORIC 56.26
- MLYS 43.56
- Support Level
- ORIC $9.39
- MLYS $9.18
- Resistance Level
- ORIC $11.15
- MLYS $9.97
- Average True Range (ATR)
- ORIC 0.74
- MLYS 0.85
- MACD
- ORIC 0.16
- MLYS -0.08
- Stochastic Oscillator
- ORIC 60.49
- MLYS 38.05
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.